Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.

Sep 17, 2025 · Introduction: About 10% to 20% of newly diagnosed breast cancers are HER2-positive [1-2]. HER2-positive tumors have a lot of the protein called HER2 on the surface of …

Dec 2, 2025 · Targeted therapy is a treatment for certain types of breast cancer. Learn about types of targeted therapy, common side effects, and more.

1 day ago · For Your Patients: What to Know About the Newest Treatments for HR+/HER2- Breast Cancer — Resistance to initial therapy sets the stage for many other options

3 days ago · The efficacy of contemporary cancer treatments can be attributed to novel targeted and immunotherapeutic agents capable of selectively targeting cancer cells, such as CDK4/6 …

Jun 17, 2025 · The current treatment landscape for HER2-positive metastatic breast cancer has evolved significantly, with recent updates further refining patient care strategies. Historically, …

3 days ago · Conclusions: Tucatinib addition to trastuzumab and pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L …

2 days ago · As such, there is an unmet need for developing more effective first-line maintenance treatments in HER2-positive metastatic breast cancer.

Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive …

Trastuzumab (Herceptin) is a targeted therapy for treating breast cancer. Find out when it's used, how it works and possible side effects.